$126 Million is the total value of DAFNA Capital Management LLC's 95 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGTC | APPLIED GENETIC TECHNOL CORP | $2,362,000 | +1.1% | 167,192 | 0.0% | 1.87% | -7.1% | |
| INSULET CORPnote 2.000% 6/1 | $2,294,000 | -1.5% | 2,407,000 | 0.0% | 1.82% | -9.6% | ||
| ACHN | ACHILLION PHARMACEUTICALS | $1,845,000 | +1.0% | 236,500 | 0.0% | 1.46% | -7.2% | |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $1,644,000 | 0.0% | 2,500,000 | 0.0% | 1.30% | -8.1% | ||
| BSTC | BIOSPECIFICS TECHNOLOGIES | $1,586,000 | +14.8% | 39,704 | 0.0% | 1.26% | +5.5% | |
| IBB | ISHARES TR NASDQ BIOTECetf | $1,544,000 | -1.3% | 6,000 | 0.0% | 1.22% | -9.3% | |
| SPNC | SPECTRANETICS CORP | $1,493,000 | +28.8% | 79,812 | 0.0% | 1.18% | +18.3% | |
| MGNX | MACROGENICS INC | $1,463,000 | +44.0% | 54,200 | 0.0% | 1.16% | +32.4% | |
| DSCI | DERMA SCIENCES INC | $1,394,000 | +27.1% | 353,718 | 0.0% | 1.10% | +16.8% | |
| STXS | STEREOTAXIS INC | $1,345,000 | -10.9% | 1,372,862 | 0.0% | 1.07% | -18.2% | |
| CARA | CARA THERAPEUTICS INC | $1,284,000 | -22.7% | 267,046 | 0.0% | 1.02% | -29.0% | |
| QURE | UNIQURE B.V. | $1,171,000 | -38.0% | 158,907 | 0.0% | 0.93% | -43.0% | |
| JNJ | JOHNSON AND JOHNSON | $1,140,000 | +12.1% | 9,400 | 0.0% | 0.90% | +3.1% | |
| NVDQ | NOVADAQ TECHNOLOGIES INC | $1,002,000 | -11.2% | 101,841 | 0.0% | 0.79% | -18.5% | |
| EXAC | EXACTECH INC | $846,000 | +32.0% | 31,636 | 0.0% | 0.67% | +21.3% | |
| ESSA PHARMA INC | $810,000 | +22.4% | 202,496 | 0.0% | 0.64% | +12.4% | ||
| ASND | ASCENDIS PHARMAsponsored adr | $707,000 | -28.4% | 53,241 | 0.0% | 0.56% | -34.3% | |
| ELOS | SYNERON MEDICAL LTD | $661,000 | +5.3% | 85,947 | 0.0% | 0.52% | -3.3% | |
| BGNE | BEIGENE LTDsponsored adr added | $596,000 | +1.7% | 20,000 | 0.0% | 0.47% | -6.5% | |
| CYNAPSUS THERAPEUTICS INC | $564,000 | +35.6% | 33,995 | 0.0% | 0.45% | +24.5% | ||
| INTEC PHARMA LTD JERUSALEM | $549,000 | +11.8% | 119,296 | 0.0% | 0.44% | +2.6% | ||
| TARGACEPT INCnote 2/1 | $531,000 | 0.0% | 530,821 | 0.0% | 0.42% | -8.1% | ||
| BLUE | BLUEBIRD BIO INC | $519,000 | +1.8% | 12,000 | 0.0% | 0.41% | -6.6% | |
| ABEO | ABEONA THERAPEUTICS INC | $429,000 | -7.7% | 181,818 | 0.0% | 0.34% | -15.2% | |
| VTVT | VTV THERAPEUTICS INCcl a | $423,000 | +12.2% | 73,000 | 0.0% | 0.34% | +3.1% | |
| NEOS | NEOS THERAPEUTICS INC | $361,000 | -13.8% | 38,873 | 0.0% | 0.29% | -20.8% | |
| CGNT | COGENTIX MEDICAL INC | $339,000 | -12.6% | 352,882 | 0.0% | 0.27% | -19.7% | |
| SNSS | SUNESIS PHARMACEUTICALS INC | $232,000 | +1.3% | 423,336 | 0.0% | 0.18% | -7.1% | |
| TENX | TENAX THERAPEUTICS INC | $204,000 | +25.2% | 79,509 | 0.0% | 0.16% | +14.9% | |
| CBIO | CATALYST BIOSCIENCES INC | $108,000 | -9.2% | 70,903 | 0.0% | 0.09% | -16.5% | |
| NVLS | NIVALIS THERAPEUTICS INC | $69,000 | +9.5% | 15,000 | 0.0% | 0.06% | +1.9% | |
| CVM | CEL SCI CORP | $59,000 | -13.2% | 127,482 | 0.0% | 0.05% | -20.3% | |
| GNVC | GENVEC INC | $55,000 | -28.6% | 95,800 | 0.0% | 0.04% | -33.3% | |
| ATRS | ANTARES PHARMA INC | $47,000 | +20.5% | 45,000 | 0.0% | 0.04% | +8.8% | |
| ETRM | ENTEROMEDICS INC COM PAR 0.01 | $10,000 | -68.8% | 33,334 | 0.0% | 0.01% | -71.4% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.